Tian An Medicare Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Tian An Medicare için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Healthcare kazanç büyümesi	21.1%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

China Medical & HealthCare Group's (HKG:383) Returns On Capital Not Reflecting Well On The Business

Feb 02

Returns On Capital Signal Difficult Times Ahead For China Medical & HealthCare Group (HKG:383)

Oct 26

Is China Medical & HealthCare Group (HKG:383) Using Debt In A Risky Way?

Sep 30

China Medical & HealthCare Group (HKG:383) Might Have The Makings Of A Multi-Bagger

Dec 10

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Tian An Medicare yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

SEHK:383 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (HKD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	1,629	32	-12	226	N/A
3/31/2024	1,599	21	74	291	N/A
12/31/2023	1,569	11	160	356	N/A
9/30/2023	1,516	-32	112	277	N/A
6/30/2023	1,463	-78	63	197	N/A
3/31/2023	1,450	-101	-2	134	N/A
12/31/2022	1,438	-124	-68	70	N/A
9/30/2022	1,464	-115	-18	120	N/A
6/30/2022	1,491	-107	31	169	N/A
3/31/2022	1,477	-122	48	194	N/A
12/31/2021	1,463	-137	65	219	N/A
9/30/2021	1,447	-127	36	176	N/A
6/30/2021	1,430	-116	7	133	N/A
3/31/2021	1,312	-114	-55	59	N/A
12/31/2020	1,194	-112	-116	-16	N/A
6/30/2020	1,099	-81	-109	32	N/A
3/31/2020	1,163	-40	-14	104	N/A
12/31/2019	1,228	1	81	176	N/A
6/30/2019	1,196	35	-95	-51	N/A
3/31/2019	1,168	-8	272	327	N/A
12/31/2018	1,139	-52	639	705	N/A
9/30/2018	1,120	-94	776	839	N/A
6/30/2018	1,101	-137	913	973	N/A
3/31/2018	1,115	-198	N/A	495	N/A
12/31/2017	1,130	-258	N/A	16	N/A
9/30/2017	1,207	-165	N/A	100	N/A
6/30/2017	1,284	-72	N/A	184	N/A
3/31/2017	1,791	-143	N/A	296	N/A
12/31/2016	2,297	-214	N/A	408	N/A
9/30/2016	2,349	-498	N/A	88	N/A
6/30/2016	2,400	-783	N/A	-232	N/A
3/31/2016	1,787	-375	N/A	N/A	N/A
12/31/2015	1,175	33	N/A	37	N/A
9/30/2015	945	131	N/A	325	N/A
6/30/2015	715	228	N/A	613	N/A
3/31/2015	859	233	N/A	N/A	N/A
12/31/2014	1,003	237	N/A	926	N/A
9/30/2014	1,050	582	N/A	480	N/A
6/30/2014	1,096	928	N/A	34	N/A
12/31/2013	219	-363	N/A	-580	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 383 'un tahmini kazanç büyümesinin tasarruf oranının ( 2.3% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: 383 'un kazançlarının Hong Kong pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: 383 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: 383 şirketinin gelirinin Hong Kong pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: 383 şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 383 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Tian An Medicare Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

China Medical & Healthcare Group Limited Provides Earnings Guidance for Eleven Months Ended 30 November 2023

China Medical & HealthCare Group Limited Provides Group Earnings Guidance for the Five Months Ended 31 May 2023

China Medical & Healthcare Group Limited Provides Consolidated Earnings Guidance for the Eleven Months Ended 30 November 2022

China Medical & HealthCare Group Limited Provides Unaudited Consolidated for the Five Months Ended 31 May 2022

China Medical & HealthCare Group Limited Provides Unaudited Consolidated Earnings Guidance for the Four Months Ended April 30, 2021

Recent updates

New minor risk - Market cap size

First half 2024 earnings released: EPS: HK$0.02 (vs HK$0.002 in 1H 2023)

First half 2024 earnings released: EPS: HK$0.02 (vs HK$0.002 loss in 1H 2023)

Tian An Medicare Limited to Report Q4, 2024 Results on Aug 02, 2024

Upcoming dividend of HK$0.01 per share

Full year 2023 earnings released: EPS: HK$0.012 (vs HK$0.17 loss in FY 2022)

China Medical & Healthcare Group Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 02 August 2024

Full year 2023 earnings released: EPS: HK$0.012 (vs HK$0.17 loss in FY 2022)

China Medical & HealthCare Group Limited, Annual General Meeting, May 20, 2024

China Medical & HealthCare Group Limited to Report Fiscal Year 2023 Final Results on Mar 15, 2024

New minor risk - Market cap size

China Medical & Healthcare Group Limited Provides Earnings Guidance for Eleven Months Ended 30 November 2023

China Medical & Healthcare Group Limited Announces Company Secretary and Authorised Representative Changes

China Medical & HealthCare Group Limited Announces Change in the Composition of the Board of Directors and Change of Members of the Board Committees

Tian An China Investments Company Limited (SEHK:28) completed the acquisition of 18.13% stake in China Medical & HealthCare Group Limited (SEHK:383) from its shareholders for approximately HKD 180 million.

China Medical & Healthcare Group Limited Announces Resignation of Chong Sok Un as Executive Director and Deputy Chairman and Change in Composition of the Board Committees

First half 2023 earnings released: HK$0.002 loss per share (vs HK$0.061 loss in 1H 2022)

New major risk - Revenue and earnings growth

China Medical & HealthCare Group Limited to Report Second Half, 2023 Results on Aug 18, 2023

China Medical & HealthCare Group Limited Provides Group Earnings Guidance for the Five Months Ended 31 May 2023

Full year 2022 earnings released: HK$0.17 loss per share (vs HK$0.19 loss in FY 2021)

China Medical & HealthCare Group's (HKG:383) Returns On Capital Not Reflecting Well On The Business

China Medical & Healthcare Group Limited Provides Consolidated Earnings Guidance for the Eleven Months Ended 30 November 2022

Less than half of directors are independent

China Medical & Healthcare Group Limited Announces Executive Changes

Returns On Capital Signal Difficult Times Ahead For China Medical & HealthCare Group (HKG:383)

Is China Medical & HealthCare Group (HKG:383) Using Debt In A Risky Way?

First half 2022 earnings released: HK$0.003 loss per share (vs HK$0.005 loss in 1H 2021)

China Medical & HealthCare Group Limited Provides Unaudited Consolidated for the Five Months Ended 31 May 2022

Less than half of directors are independent

Full year 2021 earnings released: HK$0.009 loss per share (vs HK$0.008 loss in FY 2020)

China Medical & HealthCare Group Limited, Annual General Meeting, Jun 01, 2022

China Medical & HealthCare Group (HKG:383) Might Have The Makings Of A Multi-Bagger

First half 2021 earnings released: HK$0.005 loss per share (vs HK$0.005 loss in 1H 2020)

First half 2021 earnings released: HK$0.005 loss per share (vs HK$0.005 loss in 1H 2020)

China Medical & HealthCare Group Limited Provides Unaudited Consolidated Earnings Guidance for the Four Months Ended April 30, 2021

Executive Director has left the company

Non-Executive Director has left the company

Chairman Liye Zhou has left the company

We Think China Medical & HealthCare Group (HKG:383) Has A Fair Chunk Of Debt

China Medical & HealthCare Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Do Institutions Own China Medical & HealthCare Group Limited (HKG:383) Shares?

Is China Medical & HealthCare Group (HKG:383) A Risky Investment?

China Medical & Healthcare Group Limited Appoints Lai Hin Wing Henry Stephen as Non-Executive Director, Effective November 11, 2020

First half earnings released

China Medical & HealthCare Group Limited to Report 18 Months Period Ending Dec 31, 2019 Results on Mar 30, 2020

China Medical & HealthCare Group Limited to Report Second Half, 2020 Results on Aug 27, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin